We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tissue Regenix Group Plc | LSE:TRX | London | Ordinary Share | GB00BNTXR104 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.30 | 2.16% | 61.50 | 61.00 | 62.00 | 61.50 | 61.50 | 61.50 | 53,456 | 08:00:23 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 24.48M | -2.7M | -0.0382 | -16.10 | 43.4M |
Date | Subject | Author | Discuss |
---|---|---|---|
10/5/2021 10:46 | Someone drip feeding into the demand. | cynic1 | |
10/5/2021 10:25 | Directors buying can only be a good thing expect this share to start a March up from here my price target year end .90 | tnt99 | |
01/5/2021 10:05 | (FAB) Fusion Antibodies is making antibodies for COVID vaccine companies. The stock is tightly held, and valued at 43m. It is fully funded by grants. Do your own research, and I am sure you will all be very impressed. | abeygale | |
30/4/2021 08:15 | and a modest punt for me, this sunny morning. (+ Edit) nice finish to the day. chart looks very good for next week. | judge grinder | |
29/4/2021 17:07 | Great timing Lombard Odier fund has added, they must read my posts lol Onwards & upwards | ny boy | |
29/4/2021 08:17 | I thought that both the CEo and CFO came across well in the IMC meeting and would encourage you to listen to it as both the presentation and the Q&A were good. The update this morning from S&N on elective surgery was reassuring. TRX said definitive pick up of demand in the US but still long way from preCovid. For me have two things going for them. What seems to be a stable share holder register and no need to raise funds. | cerrito | |
28/4/2021 19:37 | I was multitasking at work :) will try and listen to the recording. I'm surprise to see 0.55 though, and annoyed I bought a couple of weeks ago at 0.6. Oh well. | ultrasilva | |
28/4/2021 16:37 | Is anyone on the investor meet company live presentation ??? | dubai123 | |
28/4/2021 15:31 | Disappointed by the downward share price movement. Another share of mine [SUN] which is involved in (stalled) elective surgery is progressing much better. | contact2fsnetcouk | |
28/4/2021 15:09 | Interesting update , showing very reasonable results & good prospects. I can't find Note 12 which is referred to , & just hope that the 'annual impairment test' relating to the goodwill value of the CellRight Technology, £6.1million this time, doesn't recur at anything like the same level. | dogwalker | |
28/4/2021 12:45 | I’m going to add another 100k on this retrace, 2nd half should be pleasing, taking a long term view, a bit like when I got a used buying ITX @ 2p and under, now 12p, takes time to make reasonable gains. | ny boy | |
28/4/2021 08:37 | Nothing new here then just keeping everything under the hat but should be good news in the long run with new products coming on line and this mysterious white products contract with a top ten healthcare companyProbably as Covid is still impacting sales somewhat but expected to rise in the second half of the year to what I hope is at least break even | tnt99 | |
28/4/2021 08:00 | "The year was primarily highlighted by our financial performance relative to other industry participants, and securing the necessary funding to support the organisation and invest in the required capacity expansion programme. Alongside this, we secured a number of additional distribution and white label agreements for organic growth in the US and extending our geographical outreach through the receipt of the CE Mark for OrthoPure(R)XT which allowed us to begin our commercialisation efforts within the EU. As COVID restrictions subside and with the backdrop of a material global backlog of elective surgeries, we expect strong growth in product demand in the second half of 2021 and are well positioned to capture and service this need with our extensive product lines. | meganxmas | |
28/4/2021 07:49 | Would have been good to have had some comment on current trading | cerrito | |
27/4/2021 17:05 | Wil, I agree - very confusing - my top up purchase was shown as a sell and looking forward to a positive presentation. | contact2fsnetcouk | |
27/4/2021 11:02 | No. We are all equally bullish, like you. Which makes this a sell. | dogwalker | |
27/4/2021 09:43 | The share 'buys' and 'sells' are most misleading- the 312,848 showing in red was a buy. On the face of what I have read why would there be so much selling ? The year end figures might not be scintillating but the story here looks so exciting and I can't help a strong feeling that the presentation on Wed afternoon will be thoroughly positive. Does anyone here think otherwise ? | wiloughby2 | |
25/4/2021 18:43 | One of those TR1s is a correction of an earlier one. | ultrasilva | |
24/4/2021 11:11 | "Selling in volume" - you mean the odd 0.5% or 1%?? Mesmells a deramper... | cyberbub | |
23/4/2021 19:52 | Recent RNS filings show key institutional investors selling in volume. Do they know something we don't? | b1inkers | |
23/4/2021 18:30 | Shame it seems to be moving relentlessly backwards! | jpuff | |
23/4/2021 10:36 | @willoughby2 I can't take any credit for that, it was posted by ragnarr originally, see #6229 :) | ultrasilva | |
23/4/2021 04:37 | Ultrasilva thank you for the link you posted no 6510 for Reddit.Anybody remotely interested in TRX would find this article interesting. Perhaps it could be made available in the header ?Keep up the good work. At 0.6 p one can tuck away enough to make a real difference to a SIPP portfolio further down the line. | wiloughby2 | |
19/4/2021 18:34 | Might buy a few more before the meeting | contact2fsnetcouk |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions